MariTide Tracker
Track the Once-Monthly GLP-1/GIP Antibody Injection
MariTide is Amgen's monthly weight-loss injection — one shot per month producing 17–20% weight loss in Phase 2. Track monthly doses, weight progress, and side effects with Shotlee as Phase 3 trials advance toward FDA approval.
What is MariTide?
MariTide (maridebart cafraglutide) is Amgen's pipeline drug for obesity treatment. It is structurally unique: a human monoclonal antibody against the GIP receptor (antagonist — blocking GIP), conjugated with two GLP-1 receptor agonist peptides. This dual mechanism is pharmacologically different from both Ozempic (GLP-1 only) and Mounjaro (GLP-1 + GIP agonist).
The antibody backbone gives MariTide a half-life of approximately 4 weeks, enabling once-monthly subcutaneous dosing. Phase 2 results from a 52-week study showed 17% weight loss in people without type 2 diabetes and 20% in those with diabetes — remarkable for a once-monthly injection.
Phase 3 trials are actively enrolling as of 2026. FDA approval is anticipated around 2027–2028 if trials succeed. Shotlee tracks MariTide monthly injection schedules for trial participants and early patients.
FAQ
What is MariTide?
MariTide is Amgen's once-monthly subcutaneous injection for obesity — a GIP receptor antagonist antibody conjugated to GLP-1 agonist peptides. Phase 2 showed 17–20% weight loss. Phase 3 is ongoing.
Why is a monthly injection a big deal?
Most current GLP-1 medications require weekly injections. One injection per month dramatically reduces the burden of treatment and could improve adherence for the millions who struggle with weekly injections.
Can I track MariTide on Shotlee?
Yes — Shotlee supports monthly injection tracking with month-by-month reminders, dose logging, weight charting, and side effect monitoring for trial participants and future patients.